Displaying 85 (all) recruiting clinical trials.
-
AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs.Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
The aim of this study for low and standard risk germ cell tumor (GCT) patients is to minimize toxicity by reducing therapy while maintaining current ... -
Genetic Screening Outcomes in Movement Disorders
Understanding the correlation between genetic mutations and causative pathogenic mechanisms and phenotypes in Movement Disorders may significantly contribute to implementing therapeutic approaches for these conditions ... -
AGCT1532: Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours
Bleomycin, Etoposide, Cisplatin (BEP) administered 3-weekly x 4 remains standard 1st line chemotherapy for intermediate- and poor-risk metastatic germ cell tumours (GCTs). Cure rates are ... -
A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE EFFICACY SAFETY PHARMACOKINETICS AND PHARMACODYNAMICS OF SATRALIZUMAB AS MONOTHERAPY OR IN ADDITION TO BASELINE THERAPY IN PATIENTS WITH MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD)
This Phase III, randomized, double-blind (DB), placebo-controlled, multicenter study is designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab compared with placebo as ... -
Primary Ciliary Dyskinesia Foundation (PCDF) Registry: A longitudinal study of patients with primary ciliary dyskinesia
PCD Foundation (PCDF) Registry: A longitudinal study of patients with primary ciliary dyskinesia Establishment of a registry will allow for an improved understanding of demographics ... -
Parkinson s Foundation PD GENEration Genetic Registry
The Parkinson’s Foundation PDGENEration Genetic Registry study is a prospective registry study of people who are clinically diagnosed with PD. The participants will consist ... -
A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED MULTICENTER OUTPATIENT PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF STACCATO ALPRAZOLAM IN PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH EPILEPSY WITH A PREDICTABLE SEIZURE PATTERN.
Staccato alprazolam is being developed for the indication of rapid cessation of a prolonged focal or generalized seizure that has not progressed to status epilepticus ... -
CBYL719F12201: EPIK-P2 Phase II double-blind study w/ upfront 16-week randomized placebo-controlled period to assess efficacy safety & pharmacokinetics of alpelisib (BYL719) in pediatric & adult patients w/ PIK3CA-related overgrowth spectrum (PROS)
This study will be the first prospective study of alpelisib in participants with PROS. Local overgrowth or hemihypertrophy, mostly progressive, is the most frequently observed ... -
Digital Phenotyping: A Novel Method to Predict Proximal Suicide Risk in Youth
The goal of this study is to use keyboard metadata, a method of collecting data from written communications entered on iPhones, in addition to traditional ... -
bhng 0A Phase 1/2 Open-label Study to Investigate the Safety Efficacy and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults with Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
This is a multicenter, single arm, open-label, combined 2-part phase 1/2 dose escalation and expansion study in adult subjects with R/R B-ALL, evaluating ...